23andMe cuts 40% of its workforce and discontinues therapeutics division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe cuts 40% of staff in restructuring
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. “We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
Genetic testing giant 23andMe cuts 40% of workforce, discontinues therapeutics division
The restructuring arrives during a period of turmoil at the company that has included a high-profile data breach and several rounds of previous layoffs.
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
Rolling Out13h
23andMe cuts 40 percent of staff amid major business overhaul
This decision, described by CEO Anne Wojcicki as “difficult but necessary,” comes as the genetic testing company ...
Business 2 Community21d
Anne Wojcicki Net Worth: 23andMe Stock Price Woes Leaves a $200 Million Fortune
American businesswoman Anne Wojcicki is the co-founder and CEO of genetic testing company 23andMe. She became a billionaire after the company went public in 2021 but since then, the company’s ...
23andMe is laying off 40 percent of its staff
More than 200 employees of 23andMe are being laid off as part of the company’s ongoing cost-cutting measures. The layoffs ...
Black Enterprise12h
23andMe Lays Off 40% Of Employees As Company Undergoes Restructuring
Regarding its workforce reduction, which will total 200 employees, CEO Anne Wojcicki called the layoffs a “difficult but necessary” step to keep the company alive. “We are taking these difficult ...
The Financial Times28d
Founder Anne Wojcicki races to rescue 23andMe
That request epitomises the fall of a company that transformed its chief executive and founder Anne Wojcicki, ex-wife of Google founder Sergey Brin, into a paper billionaire when it floated three ...
Yahoo Finance26d
Behind the scenes at 23andMe, questions about a star CEO
Anne Wojcicki, CEO of 23andMe, the struggling DNA testing company, doesn’t think this is the right time to examine her leadership style. “What will be most interesting is writing the story in ...